Rachel Upjohn Building, East Medical Campus
Ann Arbor, Michigan, 48109-2700, United States
NCT Number: NCT01993108
The goal of this research is to understand the functioning of 'regulatory circuits' in the brain. We are also interested in how the medications methylphenidate and naltrexone affect these regulatory circuits. This research study will use a scanning technique known as functional magnetic resonance imaging (fMRI) which takes a special kind of picture of the brain that enables us to "see the brain at work". Adult participants will be given a one-time dose of either methylphenidate, naltrexone,or placebo before each fMRI scan session.
The main purpose for this research is to better understand the functioning of regulatory circuits in healthy individuals and individuals with psychiatric disorders. This research may one day help us develop better treatments for these disorders.
Looking for future studies?
Notify Me18 year–35 year
All sexes
Interventional
Phase 4
Ann Arbor, Michigan, 48109-2700, United States
The goal of this research is to understand the functioning of 'regulatory circuits' in the brain. These are brain circuits which allow a person to regulate their attention, regulate their behavioral responses, and regulate their decision-making. We are also interested in how the medications methylphenidate and naltrexone affect these regulatory circuits. Methylphenidate is a widely-used, FDA approved medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) and is also known as Ritalin. Naltrexone is an FDA approved medication used to help treat alcohol and substance abuse.
This research study will use a scanning technique known as functional magnetic resonance imaging (fMRI)which takes a special kind of picture of the brain that enables us to "see the brain at work". Adult participants will be given a one-time dose of either methylphenidate, naltrexone,or placebo before each fMRI scan session. There are three total fMRI scan sessions. Therefore, each participant will receive each possible medication/placebo only once.
Using the fMRI technique, the main purpose of this research is to better understand the functioning of regulatory circuits in healthy individuals and individuals with psychiatric disorders. This research may one day help us develop better treatments for these disorders.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for all study participants:
Exclusion criteria
for all study participants:
Inclusion criteria
for the participants with ADHD:
One dose 40mgs of methylphenidate one hour before fMRI scanning.
Other names: Ritalin
One dose 40mgs of naltrexone one hour before fMRI scanning.
Other names: ReVia
One dose of placebo one hour before fMRI scanning.
Other names: sugar pill
Time frame: 2 hours
Multi-Source Interference Task is a psychological task that measures the psychological construct of cognitive control, the ability to suppress automatic response tendencies. Reaction time variability is the standard deviation of the trial to trial reaction time measured in seconds.
Time frame: Two hours
Reaction time of the Multi-Source Interference Task is measured in seconds.
Time frame: Two hours
Accuracy is the calculated percentage of correct responses over total trials in the Multi-Source Interference Task.
Time frame: Two hours
The effects of methylphenidate, naltrexone, and placebo on the change in BOLD (Blood Oxygen Level Dependent) signal will be characterized in the incongruent condition (cognitive regulation condition) of the MSIT (multi-source interference task) relative to the congruent condition (no regulation condition). Specifically, the summed BOLD signal in three regions--dorsal lateral prefrontal cortex, anterior insula, anterior cingulate--are measured.
University of Michigan
Other
Control of Cognition: Naltrexone, Methylphenidate, and ADHD Study
Acronym: NMAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01554462
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder
Utrecht, Netherlands
View Trial DetailsNCT04095377
ABD, ADHD
Rishon LeZiyyon, Israel
View Trial DetailsNCT03832413
ABD, ADHD
Rishon LeZiyyon, Israel
View Trial DetailsNCT00008892
Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder with Hyperactivity
Bethesda, Maryland, United States
View Trial Details